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ABSTRACT: 
Crystal structures can identify ligand-receptor interactions and assist the development of novel 
therapeutics, but experimental challenges sometimes necessitate the use of homologous proteins. 
Tropisetron is an orthosteric ligand at both 5-HT3 and α7 nACh receptors and its binding orientation 
has been determined in the structural homologue AChBP (pdbid: 2WNC). Co-crystallisation with a 
structurally-related ligand, granisetron, reveals an almost identical orientation (pdbid; 2YME). 
However, there is a > 1000-fold difference in the affinity of tropisetron at 5-HT3 versus α7 nACh 
receptors, and α7 nACh receptors do not bind granisetron. These striking pharmacological 
differences prompt questions about which receptor the crystal structures most closely represent and 
whether the ligand orientations are correct. Here we probe the binding orientation of tropisetron 
and granisetron at 5-HT3 receptors by in silico modelling and docking, radioligand binding on 
cysteine-substituted 5-HT3 receptor mutants transiently expressed in HEK 293 cells, and synthetic 
modification of the ligands. For 15 of the 23 cysteine substitutions, the effects on tropisetron and 
granisetron were different. Structure-activity relationships on synthesised derivatives of both ligands 
were also consistent with different orientations, revealing that contrary to the crystallographic 
evidence from AChBP, the two ligands adopt different orientations in the 5-HT3 receptor binding 
site. Our results show that even quite structurally similar molecules can adopt different orientations 
in the same binding site, and that caution may be needed when using homologous proteins to 
predict ligand binding. 
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INTRODUCTION: 
Tropisetron (e.g. Navoban®, ICS 205-930), granisetron (e.g. Kytril®, Sancuso®, GranisolTM) and 
other structurally-related drugs are used to alleviate the symptoms of nausea and vomiting following 
general anaesthesia, cancer chemotherapy and radiotherapy (Thompson, 2013). The therapeutic effect 
of these is due to their high-affinity competitive block of 5-HT3 receptors in the gut and brain stem.  
5-HT3 receptors belong to the Cys-loop family of transmembrane ligand-gated ion-channels 
that are responsible for fast synaptic neurotransmission in the central and peripheral nervous systems. 
All members of this family are composed of five subunits, each of which contains an extracellular, a 
transmembrane and an intracellular domain (Miller and Smart, 2012; Thompson et al., 2010). Binding 
of tropisetron and granisetron to extracellular binding sites blocks the action of the native agonist 5-HT. 
These binding sites are at the interface of two adjacent subunits and form a hydrophobic cavity that is 
composed of amino acids from loops A - C in the principal subunit interface and loops D - F in the 
complementary subunit interface (fig 1).  
Crystallisation studies have attempted to evaluate the binding orientations of several 5-HT3 
receptor ligands, but all of these have been performed on a close structural homologue rather than the 
native receptor. For example, cocaine (pdbid; 2PGZ) and tropisetron (2WNC) were crystallised in the 
binding site of acetylcholine binding protein (AChBP), while granisetron (2YME) was crystallised with an 
AChBP mutant containing two loop D amino acids substitutions that increased its affinity for this ligand 
(Hansen and Taylor, 2007; Hibbs et al., 2009; Kesters et al., 2013). Other studies have sought to explore 
the binding orientation of granisetron using homology modelling and ligand docking, but the majority 
of these are over a decade old and do not benefit from our improved understanding of the receptor 
family or developments in the computer software used to model them (reviewed in Thompson et al., 
2010). For example, the apo crystal structure of the mouse 5-HT3 receptor was published in 2014 and 
has provided an unprecedented insight into the native structure in the absence of a ligand (Hassaine et 
al., 2014).  
In addition to high affinity competitive antagonism at 5-HT3 receptors, tropisetron is also 
reported to bind to the α7 nACh receptor which belongs to the same Cys-loop receptor family (Macor 
et al., 2001; Papke et al., 2005). However, at α7 nACh receptors tropisetron causes activation. In 
contrast, at the same receptor, binding of the very close granisetron congener and 5-HT3 receptor 
antagonist LY-278,584 cannot be detected (Macor et al., 2001). Despite these pharmacological 
differences, in co-crystal structures with the homologue AChBP, tropisetron and granisetron adopt 
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almost identical positions and orientations in the binding site. Given the quite distinct pharmacological 
properties of these ligands it is therefore unclear whether the structures are true representations of 
the orientations found at 5-HT3 or α7 nACh receptors, and if they are, which of the two receptors the 
AChBP co-crystal structures most closely resemble. 
Here we probe the binding orientations of tropisetron and granisetron at 5-HT3 receptors, using 
a combination of bioinformatics, cysteine mutagenesis and the synthesis of ligand analogues. The 
results show that their orientations differ, and question whether it is appropriate to use these receptor 
homologues for predicting ligand binding at different members of the Cys-loop family. 
  
RESULTS 
Docking: To gain insights into potential binding-site interactions, residues located within 5 Å of 
tropisetron or granisetron were identified from four sources; (1) tropisetron in the AChBP co-crystal 
structure 2WNC, (2) granisetron in the AChBP co-crystal structure 2YME, (3) in silico docking of 
tropisetron into a 5-HT3 receptor homology model based upon 2WNC, and (4) in silico docking of 
tropisetron into 2YME (fig 2). From the analysis of the resultant 22 ligand orientations, a total of 33 
residue positions were identified as being within 5 Å of a ligand, and were located throughout the 
binding loops A - E (table 1, fig 1). Five of the residues were common to all predicted ligand orientations 
(W90, N128, W183, Y234, Y153). Sixteen other residues (K112, I127, E129, Y141, V142, Y143, V150, 
N152, K154, P155, T179, F180, T181, H185, A235, E236) were unique to only one of the four predictions 
(table 1). The remaining 12 residues (D69, I71, R92, Q151, L126, S182, L184, M228, E229, S230, S231, 
N232) were distributed in at least two of the predictions. Of the 33 identified residues, 23 were 
mutated to cysteine. 
Radioligand Binding: Untransfected HEK293 cells showed no saturable binding with 
[3H]tropisetron or [3H]granisetron, but upon transient expression of wild type 5-HT3 receptors both 
ligands displayed high-affinity saturable binding (tables 2 & 3). Non-specific binding was 30.3 ± 1.8 % (n 
= 8) of total for tropisetron and 6.7 ± 0.4 % (n = 6) for granisetron. Kd values were similar to those 
reported elsewhere (Neijt et al., 1988; Thompson et al., 2005). 
Effects of Mutations on Tropisetron Binding: The binding affinity of [3H]tropisetron at each of 
the mutant receptors is shown in table 2 and their locations in the 5-HT3 receptor binding site in fig 3. 
Changing 7 of the 23 residues caused no significant change in affinity when compared to wild type 
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receptors, suggesting they do not have a significant role in ligand binding or the structure of the binding 
site (I71, Q151, T179, L184, S230, S231, N232). For the remaining 16 mutants there were differences in 
the binding affinities, indicating that these residues may interact with the ligand or alter the receptor 
structure. Of these, 9 had reduced affinities (R92C, L126, N128, Y153, P155, T181, M228, E229, E236) 
and 7 showed no saturable binding (Kd > 20 nM; D69, W90, E129, Y143, W183, H185, Y234). 
Effects of Mutations on Granisetron Binding: Crystal structures of tropisetron or granisetron 
bound to the homologue AChBP (fig 2C) reveal very similar ligand orientations (Hibbs et al., 2009; 
Kesters et al., 2013). To determine whether these two ligands also adopt such similar poses in the 5-HT3 
receptor we performed saturation binding with radiolabelled granisetron on the same mutants used for 
the tropisetron study. Of the 23 substitutions, 8 similarly affected granisetron binding, while the 
remaining 15 showed differing effects for the two ligands (table 3, fig 3). Of those that were similar, the 
substitutions W90C, E129C and W183C abolished binding, Y153C reduced the affinity, and Q151C, 
L184C, S231C and N232C had no effect. In contrast to tropisetron, saturable binding of granisetron 
could be detected with D69C, Y143C and H185C, the mutants I71C, T179C and Y234C showed a 
significant decrease in affinity, S230C increased the affinity, R92C and T181C did show saturable 
binding, and binding was unaltered by substitutions at L126C, N128C, P155C, M228C, E229C, and 
E236C. 
Western Blot of Non-Binding Mutants: Three of the mutant receptors did not bind 
[3H]tropisetron or [3H]granisetron (W90C, E129C, W183C). To confirm that these receptors were 
expressed we performed Western blot with a 5-HT3 receptor-specific antibody. No immunostaining was 
apparent from untransfected HEK 293 cells, but clear bands were seen for wild type and mutant 
receptors at the expected size (fig 4). 
Binding of Granisetron & Tropisetron Derivatives: In addition to the changes made to the 
receptor, tropisetron and granisetron were also altered by synthesising derivatives (table 4). It was 
clear from the affinities of these derivatives that modification of the bicyclic amine (N-8’) position was 
poorly tolerated by tropisetron, while substitution at the corresponding nitrogen of granisetron (N-9’) 
was less detrimental (see table 4 for atom numbering). At the opposite end of the molecule, 
modifications at each of the three positions (C-5, C-6 and C-7) within the heteroaromatic ring of 
tropisetron reduced the binding affinity by 253-fold or less, while modification of only the C-5 position 
in granisetron caused a > 10,000-fold decrease in affinity. These structure-activity relationships (SAR) of 
tropisetron and granisetron show that the two structurally similar ligands have different substitution 
tolerance patterns with respect to 5-HT3 receptor binding.  
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Binding at α7 nACh Receptors: In contrast to its antagonist actions at 5-HT3 receptors, 
tropisetron is a partial agonist at α7 nACh receptors (Macor et al., 2001; Papke et al., 2005). A 
comparative study of its binding at these two receptor types could therefore provide insights into these 
distinct properties. However, saturation binding of [3H]tropisetron and [3H]granisetron could not be 
detected at α7 nACh receptors. In contrast, [3H]epibatidine bound with high affinity (Kd = 8.81 ± 0.13 
nM, n = 5), allowing the affinities of non-radiolabelled tropisetron and granisetron to be probed by 
competition binding. For tropisetron this gave a Ki of 1.58 ± 0.84 µM (n = 3), while competition was not 
detected for granisetron at a concentration of up to 100 µM. 
 
DISCUSSION 
Tropisetron and granisetron showed high-affinity, saturable binding at 5-HT3 receptors. For the 
majority (15/23) of cysteine substitutions we made to this receptor, the effects on binding were 
different for the two ligands, suggesting they may adopt different orientations. This observation was 
supported by our SAR on analogues of the same ligands, but conflicts with the very similar poses seen in 
co-crystal structures of these ligands bound to AChBP. 
 There have been several studies characterising the binding of orthosteric ligands at 5-HT3 
receptors and a consensus regarding their function has been further guided by the more recent mouse 
5-HT3 crystal structure 4PIR (Hassaine et al., 2014; Thompson et al., 2010). Some residues are thought 
to interact with the ligands, but others are thought to have primarily structural roles. From the crystal 
structure 4PIR it is clear that a hydrogen bond between E129 and T179 is structural (Hassaine et al., 
2014). Such an interaction is supported by our finding that E129C abolishes binding of both ligands and 
by other reports that describe similar effects on granisetron, GR65630 and VUF10166 (Boess et al., 
1997; Price et al., 2008; Thompson et al., 2005; Thompson et al., 2014). For T179C the effects on the 
two ligands were not as pronounced, but as both threonine and cysteine can act as hydrogen bond 
donors this property may be retained following substitution; consistent with this, substitution to serine 
also preserves granisetron binding (Thompson et al., 2005). L184 and H185 are also thought to make 
structural contributions by forming, respectively, hydrophobic interactions and a network of hydrogen 
bonds (Hassaine et al., 2014; Thompson et al., 2008). For L184 the absence of effects for both ligands 
were similar to previous reports of isoleucine substitution on granisetron binding, and as the sulphur in 
cysteine has a similar hydrophobic character to the side chains of leucine and isoleucine our result was 
anticipated (Nagano et al., 1999; Thompson et al., 2008). For H185 a substitution to cysteine would also 
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conserve its side-chain interactions as both residues are capable of hydrogen bonding. However, was 
previously reported that mutations at this location reduce cell-surface expression, and the lower Bmax 
value we measured for granisetron (H185C = 123 ± 23 fmol mg-1; wild type = 4843 ± 512 fmol mg-1; 
paired samples, n = 4) is consistent with this (Joshi et al., 2006; Thompson et al., 2008). For tropisetron 
it is therefore possible that the absence of binding does not reveal interactions but, given the higher 
levels of non-specific binding, instead reveals expression levels that are below the threshold for 
detection.  
 In contrast to the structural roles described above, other binding site residues are thought to 
be responsible for direct ligand interactions. For some of these, the changes in affinity were large and 
provided compelling evidence of an interaction, particularly where the effects on tropisetron and 
granisetron differed. For example, the loop B residue T181C caused a 6-fold decrease in affinity for 
tropisetron, but abolished granisetron binding. As 4PIR shows that this residue faces into the binding 
pocket, and mutations to smaller side-chains (Ala or Ser) are known to have no effect on granisetron 
binding, this difference may result from steric constraints that affect the two ligands differently  
(Thompson et al., 2008; Thompson et al., 2011; Thompson et al., 2014). In loop A, N128 also points 
towards the binding site, but consistent with the absence of specific interactions with the equivalent 
residue in 2YME (Y91), the affinity of granisetron was not altered. In previous work, a similar absence of 
effects on granisetron has also been reported for range of other substitutions at this location (Price et 
al., 2008; Sullivan et al., 2006). However, the effects we measured on the affinity of tropisetron (7-fold) 
and previous reports of changes to the EC50 of 5-HT, mCPBG and the binding affinity of VUF10166 
suggests that effects may depend upon the ligand studied (Price et al., 2008; Sullivan et al., 2006; 
Thompson et al., 2014). In P4IR, N128 lies close to L126 on loop A, and E236 in loop C, none of which 
caused significant effects on granisetron binding. In contrast, tropisetron binding was altered by 
mutation at all of these locations (7-, 2.5- & 10-fold respectively, table 2). When considered together 
this suggests that of the two ligands studied only tropisetron extends into this region of the binding 
pocket. Notably, neither L126 nor E236 are identified as lying within 5Å of tropisetron in the 
tropisetron co-crystal structure 2WNC (table 1). In contrast, both residues are predicted to lie within 5Å 
of tropisetron in Cluster-A, suggesting that our mutagenesis is more consistent with this predicted 
orientation (fig 3 & 5). 
 In loop D, R92C abolishes granisetron binding, but the affinity for tropisetron is reduced by only 
2.5-fold. In the structure 2YME the equivalent residue (R55) makes a cation-π interaction with 
granisetron and this interaction is supported by both the effect we report here and by previous findings 
that showed preserving the charge in R92K mutants does not affect granisetron binding (Duffy et al., 
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2012; Kesters et al., 2013; Thompson et al., 2005). In sharp contrast, the much smaller change in 
affinity shown by tropisetron suggest that interactions at R92 are less important. In loop E, substitution 
of the aromatic residue Y143C abolished tropisetron binding, but did not affect the binding of 
granisetron. In the AChBP crystal structures 2YME and 2WNC, neither of the ligands extends towards 
this residue and an effect would not be anticipated (fig 2). For granisetron the absence of an effect is 
consistent with the crystallographic evidence, but for tropisetron it is not. Instead, our results are more 
consistent with the in silico predictions found in cluster-A (fig 5), where tropisetron extends towards 
Y143, but is > 5Å from R92. Indeed, the orientation of tropisetron in the crystal structure 2WNC might 
be considered atypical as other α7 nACh agonists such as nicotine (1UW6), varenicline (4AFT) and 
acetylcholine (3WIP) also display low affinity binding at 5-HT3 receptors and extend towards this region 
of the binding site. D69C also abolished tropisetron binding, but did not alter the binding affinity of 
granisetron. However, D69 lies outside of the recognised binding loops and, although it was identified 
as lying within 5 Å of tropisetron in a limited number of the docked poses, it does not have an obvious 
role in our 5-HT3 receptor homology models or the AChBP crystal structures. A more likely explanation 
is that, similar to H185C, the poor expression levels revealed by granisetron (D69C = 119 ± 16 fmol mg-1; 
wild type = 4843 ± 512 fmol mg-1; paired samples, n = 4) may be below the detection threshold for 
tropisetron. 
 Other mutations abolished the binding of both ligands. For example, the effect of the aromatic 
loop B residue W183C was anticipated for both tropisetron and granisetron as it is centrally located in 
the binding pocket and strongly influences the binding of several other 5-HT3 receptor ligands 
(Thompson et al., 2010). In loop C, Y234 also contributes to the aromatic nature of the binding site, and 
our finding that tropisetron binding was abolished and the affinity of granisetron was reduced (12-fold) 
is consistent with reports that aromatic properties at this position are important (Beene et al., 2004). In 
all of the models and the AChBP crystal structures presented here, the aromatic residue Y234, or its 
equivalent (Y193), interacts with tropisetron and granisetron (Kesters et al., 2013). As a similar side 
chain orientation is seen in 4PIR, ligand interactions with this residue are also likely in the 5-HT3 
receptor binding site and are supported by the large effects we see for both ligands (Kesters et al., 
2013). Substitution of another aromatic residue, W90 in loop D, also abolished the binding of both 
tropisetron and granisetron, similar to reports for other 5-HT3 receptor ligands (Thompson et al., 2014; 
Venkataraman et al., 2002; Yan et al., 1999). Again, the aromatic character of W90 is important as 
removal of the aromatic ring (W90A, W90S) eliminates granisetron binding, but conservative 
substitutions (W90Y) have reduced effects (Price and Lummis, 2004; Spier and Lummis, 2000; 
Thompson et al., 2005; Yan and White, 2005). In contrast to the residues described above, I71C lies 
outside of the recognised binding loops but is found within 5 Å of tropisetron in a limited number of 
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the docked poses and 2WNC, and within 5 Å of granisetron in 2YME (table 1). Nevertheless, there are 
no obvious ligand interactions predicted with this residue in our models or the crystal structures and 
the similar changes in affinity seen for both ligands (1.9 & 3.4-fold) may reveal a non-specific effect. 
P155 also lies outside of the recognised binding loops, but might be anticipated to impact binding as 
prolines often distort protein backbones. It is not clear from the structural evidence why the affinity of 
granisetron was unaffected and tropisetron showed a 5-fold decrease, but it is possible that by 
distorting the backbone the positions and side-chain orientations of the other interacting residues are 
affected.   
 When residues that significantly affected tropisetron binding were compared to the residues 
predicted to lie within 5 Å of this ligand, the docked poses in Model-1 were the most consistent with 
the pattern of changes we observed. For example, residues L126 (loop A), T181, H185 (B), E236 (C) and 
Y143 (E) significantly altered the affinity for tropisetron and were also predicted in Model-1, while none 
of these were identified in either 2WNC or the poses predicted by docking tropisetron into 2YME (table 
1). Docked poses in Model-1 fell into 3 main clusters, and Cluster-A was the largest of these (fig 5). This 
cluster contained the most residues that affected binding and was the only cluster to predict that 
tropisetron extends towards Y143, a loop E substitution that abolished tropisetron binding. This cluster 
also correctly excluded residues I71 and S231 which caused little or no change when substituted (table 
2, fig 3). Although 4 other residues (T179, L184, Q151, S230) were identified as being within the 5 Å 
docking sphere of Cluster-A but had no effects on binding, none of these were predicted to directly 
interact with tropisetron; T179 and L184 are likely to have a structural role (discussed above), the side 
chain of S230 is predicted to form a hydrogen-bond with the indole NH of tropisetron that would be 
retained with a cysteine substitution, and Q151 does not make specific interactions with the ligand. 
Furthermore, in Cluster-A, the bicyclic tropane moiety of tropisetron is located close to W183, 
consistent with the cation-π interaction that unnatural amino acid mutagenesis has identified for both 
granisetron and ondansetron at this location (Duffy et al., 2012). As related molecules that contain a 
similar moiety also inhibit the 5-HT3 receptor, such as tropine and atropine, retention of this interaction 
also seems quite likely for tropisetron (Lochner and Thompson, 2016; Papke et al., 2005). Our 
mutagenesis is therefore most consistent with the position of tropisetron predicted by Cluster-A; 
although we stress that its exact orientation may differ to that shown as our docking could be biased by 
the modelling template. 
In contrast to tropisetron, the residues that affected granisetron binding were more limited in 
number and many were located at different positions (fig 3). Comparing the residues that effected 
binding with those predicted to interact with the ligand it is clear that the position of granisetron in 
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2YME is more consistent with the locations of the substitutions that altered its binding affinity. For 
example, of the 9 residues identified as being within 5 Å of granisetron in 2YME (table 1), 6 of these (I71, 
W90, R92, Y153, W183, Y234) significantly reduced the affinity of granisetron (table 3). Further, another 
10 residues that are not within 5 Å of granisetron in 2YME also had no effect on binding (D69, L126, 
Y143, P155, L184, H185, M228, E229, N232, E236). For granisetron, we suggest that the position of the 
ligand in 2YME is broadly consistent with our 5-HT3 receptor mutagenesis. 
 By synthesising tropisetron and granisetron derivatives we were also able to probe binding by 
ligand SAR. Tropisetron was more tolerant to aromatic substitutions at the C-5, C-6, C-7 indole positons, 
while incorporation of a benzyl group to the N-8’ position at the opposite end of the ligand was less 
tolerated (table 4). This SAR is most consistent with the predicted orientation for tropisetron found in 
Cluster-A as the benzyl substituent lies in a sterically unrestricted region (fig 5). Further, in the co-
crystal structure 2W8G, Ulens et al., (2009) describes a comparable orientation for cmp-35, a ligand 
that similarly contains a tropane bicycle conjugated to a benzyl ring. For granisetron, our results are 
consistent with reports showing that conjugation of a methoxy group to the C-5 position of granisetron 
is not permitted, but increased tolerance is seen as we move towards the C-7 position and the indazole 
N-1 (Vernekar et al., 2010). In 2YME the C-7 and indazole N-1 nitrogen of granisetron lies within a 
sterically unrestricted location (figs 2C & 5) and we have previously noted that attachment of bulky 
fluorophores via long linkers to each position can be accommodated (Jack et al., 2015; Simonin et al., 
2012). These results contrast with those for tropisetron, and unlike tropisetron, are consistent with the 
orientation in the crystal structure 2YME. However, this orientation of granisetron is harder to 
reconcile with the finding that a benzyl group on the sterically restricted azabicyic ring of granisetron is 
better tolerated than elaborations of the relatively unrestricted C-5 position. We therefore speculate 
that N-9’-benzyl granisetron adopts a different orientation to the parent ligand; indeed, our in silico 
docking suggests that the addition of the benzyl ring to granisetron could force it to adopt an 
orientation similar to that of the benzyl derivative of tropisetron (cmp-35) described above (data not 
shown). In summary, these results show that tropisetron and granisetron have quite distinct SAR and 
further support our proposal that these two ligands are orientated differently in the 5-HT3 receptor 
binding site.  
 Originally we had sought to probe the different orientations of tropisetron at 5-HT3 and α7 
nACh receptors and gain insights into its distinct actions at these two receptor types. However, 
saturation binding of tropisetron was undetectable at α7 nACh receptors, and a low binding affinity 
(1.58 µM) was only revealed following competition with [3H]epibatidine. This low affinity is in contrast 
to the findings of Macor et al. (2001) who reported a Ki of 6.9 nM at α7 nACh receptors, but is closer to 
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the value that might be expected for a low potency agonist (e.g. EC50 = 1.3 µM, Macor et al. 2001; 0.6 
µM, Papke et al., 2005), and to the affinity (0.5 nM) that was measured for tropisetron at AChBP and 
then used for co-crystallisation (Hibbs et al., 2009). Currently there are no mutation studies to support 
specific binding-site interactions between tropisetron and α7 nACh receptors. However, the amino acid 
sequences of AChBP and α7 nACh receptors share much stronger amino acid conservation with each 
other than with the 5-HT3 receptor and it might be expected that their binding affinities would also be 
closer (fig 1). In contrast, of the key 5-HT3 receptor residues identified for tropisetron in our study, 
N128 (Tyr in 2WNC and α7nACh), Y143 (Val in 2WNC; Leu in α7 nACh) and MESSN in loop C (CCPEP in 
2WNC; CCKEP in α7 nACh) are quite different to their equivalents in 2WNC and the α7 nACh receptor, 
and may account for the much higher affinity of 5-HT3 receptors when compared to the other two 
proteins. Indeed, the amino acid conservation and similar affinities at AChBP and the α7nACh receptor 
suggest that in fact 2WNC may better represent the binding orientation of tropisetron at the α7 nACh. 
For granisetron, AChBP and the α7 nACh receptor are less similar as this ligand has a Kd of 1 µM at 
AChBP (Kesters et al., 2013), whilst we found no detectable binding at α7 nACh receptors with  
concentrations of up to 30 µM. Several of the residues in loops A, C and D are potential candidates for 
this difference as these they make contact with granisetron and differ between all three receptors. In 
particular, the residues of loop D (YIWYRQY in 5-HT3; NIWLQMY IN α7 nACh; VYYEQQR IN 2WNC) are 
highly varied and in the 5-HT3 receptor where the loop makes direct contact with granisetron (R92 
forms a cation-π interaction) but not with tropisetron. However, it must be stressed that these 
speculations require experimental support and in future substituting AChBP and 5-HT3 residues into the 
α7 nACh receptor in an attempt to recover the higher affinities might provide clues as to which are 
important. 
 Our results confirm that both tropisetron and granisetron interact with residues in the 5-HT3 
receptor orthosteric binding site, but mutagenesis and SAR with synthetic derivatives show that they 
are likely to adopt distinct poses when they are bound. These results contrast with the almost identical 
orientations seen in co-crystal structures of these ligands bound to the structurally-related protein 
AChBP. Ligand-based virtual screening has become a popular tool to discover novel active compounds 
to modulate therapeutically interesting protein targets (Reymond et al., 2011). These approaches are 
based on the assumption that structurally similar molecules should exhibit similar binding interactions 
with the target protein and hence display the same biological activities. Our study suggests that even 
the very close structural similarity between tropisetron and granisetron does not necessarily lead to the 
same binding orientation. In addition, AChBP is sometimes used as a model for different members of 
the Cys-loop family, but our results suggest caution may be needed when interpreting ligand 
orientations in these different receptor homologues.  
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MATERIALS AND METHODS 
Radioligands: [3H]Tropisetron was synthesized (Metis Laboratories Inc, NY, USA) from its 
desmethyl analogue (0.5 mg) in a tritiomethylation reaction by heating at 80 °C for 2 h with 50 mCi 
[3H]methyl iodide in THF (0.4 mL). After evaporation of the THF the residue was subjected to reversed 
phase chromatography (Kromasil 100 C18, 7 µm, 250 x10mm, 2 mL min-1) using 31 % ACN in 0.1 % TFA 
as eluent. The eluent was stripped off and the residue was dissolved in 12 mL absolute ethanol. The 
[3H]tropisetron had a specific activity of 73.5 Ci / mmol and radiochemical purity of > 99%. 
[3H]granisetron (63.5 Ci / mmol) and [3H]epibatidine  (55.8 Ci / mmol) were purchased from Perkin 
Elmer (Waltham, MA) and were > 97% chemical purity 
Synthesis of Analogues: All reactions were performed under an inert argon atmosphere. 
Anhydrous tetrahydrofuran (THF) and CH2Cl2 were obtained by filtration through a system of alumina 
columns under a positive pressure of argon. Solvents were evaporated under reduced pressure at 
approximately 45 ºC using a Büchi Rotavapor or under high vacuum on a Schlenk line. Reagents and 
solvents were purchased from Sigma-Aldrich, Acros, Alfa Aesar, Fischer Scientific or Hänseler and used 
without further purification. Reactions were monitored by thin layer chromatography (TLC) using 
aluminum sheets pre-coated with silica gel (Macherey-Nagel ALUGRAM Xtra SII, G/UV254). Detection 
was achieved by excitation with a UV light source (λmax 254 nm) or by staining with vanillin spray, with 
subsequent heating. Flash column chromatography was carried out using silica gel from Sigma-Aldrich 
(pore size 60Å, 230–400 mesh particle size) as the stationary phase. 1H and 13C NMR spectra were 
recorded at 300 and 400 MHz, and 75 and 100 MHz respectively, on a Bruker Avance 300 and Avance II 
400. Chemical shifts are reported in δ (ppm) and are referenced to the residual solvent peak. The order 
of citation in parentheses is (1) multiplicity: s (singlet), d (doublet), t (triplet), m (multiplet) etc., (2) 
coupling constants (J) in Hz, (3) number of equivalent nuclei (by integration), and (4) assignment. Mass 
spectra and high resolution mass spectra (HRMS) were recorded on a ThermoScientific LTQ Orbitrap XL 
spectrometer consisting of a linear ion trap (LTQ) featuring a HCD collision cell, coupled to the Orbitrap 
mass analyzer, equipped with a nanoelectrospray ion source (NSI). MS and HRMS spectra were 
determined by the Mass Spectrometry Group at the Department of Chemistry and Biochemistry, 
University of Bern (PD Dr. S. Schürch). The purity of the compounds was determined by UPLC-MS on a 
Dionex Ultimate 3000 using a reversed-phase column Dionex Acclain RSLC, 120C18, 3 x 50 mm, 2.2 μm, 
120Å pore size, flow 1.2 mL/min. Following gradient was used: 30 s at 100% A, then 100% A to 100% D 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
over 5 min (A = 100% H2O with 0.1% TFA, D = H2O/MeCN 10:90 with 0.1% TFA). Purity was determined 
by total absorbance at 214 nm. 
The synthesis of substituted granisetron derivatives has been described previously (Vernekar et 
al., 2010). The synthesis of substituted tropisetron derivatives was achieved by following this general 
procedure: the corresponding indole-3-carboxylic acid (1 equiv.) was suspended in CH2Cl2. An excess of 
thionyl chloride was added and refluxed for 2 h under an argon atmosphere. After completion, the 
volatiles were removed and the solid co-evaporated with CH2Cl2. The solid was dried and used in the 
next step without purification. In a separate flask the tropine (1-2 equiv.) was dissolved in THF under 
argon and cooled to 0°C. n-Butyllithium solution (2.5 M in hexanes) was added and the resulting 
solution was stirred for 30 min at 0°C. The acid chloride intermediate previously prepared was 
dissolved in THF and added to the pre-cooled solution. The resulting mixture was stirred at 0°C for 1 h 
and at room temperature overnight. MeOH was added and the solvents were removed under reduced 
pressure. The residue was dissolved in CH2Cl2, washed with water and dried over Na2SO4. After 
filtration the organic phase was evaporated under reduced pressure. The crude was purified by column 
chromatography. 
5-Methoxy-tropisetron ((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 5-methoxy-1H-
indole-3-carboxylate) was synthesized according to the general procedure, using 5-methoxy-1H-indole-
3-carboxylic acid (50 mg, 0.26 mmol), thionyl chloride (0.5 mL, 6.9 mmol, 26 equiv.), tropine (73 mg, 
0.52 mmol, 2 equiv.) and n-butyllithium solution (2 equiv.). After purification by column 
chromatography (silica gel, CH2Cl2 / MeOH 8:2 + 0.5% aq NH3), 5-methoxy-tropisetron was obtained as 
a white solid (27 mg, 33% yield). 1H NMR (DMSO-d6) δ 1.76 (d, J=14.9, 2H, aliphatic-CH), 1.98 – 2.18 (m, 
6H, aliphatic-CH), 2.25 (s, 3H, N-Me), 3.14 (br s, 2H, aliphatic-CH), 3.78 (s, 3H, -OMe), 5.10 (t, J=5.1, 1H, 
-COO-CH-(CH2)2), 6.84 (dd, J=2.5, J=8.8, 1H, C(6)-H), 7.39 (d, J=8.8, 1H, C(7)-H), 7.51 (d, J=2.5, 1H, C(4)-
H), 7.93 (d, J=3.1, 1H, C(2)-H), 11.77 (s, 1H, NH). 1H NMR (CDCl3) δ 1.88 (d, J=14.9, 2H, aliphatic-CH), 
1.99 – 2.17 (m, 4H, aliphatic-CH), 2.23 – 2.35 (m, 2H, aliphatic-CH), 2.31 (s, 3H, N-Me), 3.19 (br s, 2H, 
aliphatic-CH), 3.80 (s, 3H, -OMe), 5.23 (t, J=5.2, 1H, -COO-CH-(CH2)2), 6.84 (dd, J=2.5, J=8.9, 1H, C(6)-H), 
7.39 (d, J=8.2, 1H, C(7)-H), 7.64 (d, J=2.4, 1H, C(4)-H), 7.74 (s, 1H, C(2)-H), 9.60 (s, 1H, NH). 13C NMR 
(CDCl3) δ 25.9, 36.4, 40.1, 55.9, 60.2, 66.2, 102.4, 108.6, 112.6, 113.9, 126.9, 131.2, 131.3, 155.9, 164.7. 
HRMS (ESI+): exact mass calcd for C18H23N2O3 [M+H]
+ 315.1703, found 315.1707, Δ: 1.2 ppm. UHPLC (λ 
= 214 nm) tR = 2.16 min, 99% purity. 
6-Methoxy-tropisetron ((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 6-methoxy-1H-
indole-3-carboxylate) was synthesized according to the general procedure, using 6-methoxy-1H-indole-
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3-carboxylic acid (35 mg, 0.183 mmol), thionyl chloride (0.3 mL, 4.14 mmol, 22 equiv.), tropine (52 mg, 
0.366 mmol, 2 equiv.) and n-butyllithium solution (2.05 equiv.). After purification by column 
chromatography (silica gel, CH2Cl2 / MeOH 8:2 + 0.5% aq NH3), 6-methoxy-tropisetron was obtained as 
a white solid (21 mg, 36% yield). 1H NMR (DMSO-d6) δ 1.78 (d, J=14.9, 2H, aliphatic-CH), 2.04 (br s, 4H, 
aliphatic-CH), 2.08 – 2.19 (m, 2H, aliphatic-CH), 2.28 (s, 3H, N-Me), 3.19 (br s, 2H, aliphatic-CH), 3.78 (s, 
3H, -OMe), 5.07 (t, J=4.9, 1H, -COO-CH-(CH2)2), 6.83 (dd, J=2.3, J=8.7, 1H, C(5)-H), 6.98 (d, J=2.2, 1H, 
C(7)-H), 7.86 (d, J=2.8, 1H, C(2)-H), 7.88 (d, J=8.6, 1H, C(4)-H), 11.67 (s, 1H, NH). 1H NMR (CDCl3) δ 1.91 
(d, J=14.8, 2H, aliphatic-CH), 2.05 – 2.15 (m, 4H, aliphatic-CH), 2.22 – 2.35 (m, 2H, aliphatic-CH), 2.34 (s, 
3H, N-Me), 3.20 (br s, 2H, aliphatic-CH), 3.83 (s, 3H, -OMe), 5.26 (t, J=5.3, 1H, -COO-CH-(CH2)2), 6.88 (d, 
J=2.1, 1H, C(7)-H), 6.93 (dd, J=2.3, J=8.7, 1H, C(5)-H), 7.74 (s, 1H, C(2)-H), 8.09 (d, J=8.7, 1H, C(4)-H), 9.19 
(s, 1H, NH). 13C NMR (CDCl3) δ 26.0, 36.6, 40.3, 55.8, 60.0, 66.5, 95.2, 109.3, 111.8, 120.3, 122.0, 130.0, 
137.2, 157.2, 164.7. HRMS (ESI+): exact mass calcd for C18H23N2O3 [M+H]
+ 315.1703, found 315.1701, Δ: 
-0.6 ppm. UHPLC (λ = 214 nm) tR = 2.19 min, 99% purity. 
7-Methoxy-tropisetron ((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 7-methoxy-1H-
indole-3-carboxylate) was synthesized according to the general procedure, using 7-methoxy-1H-indole-
3-carboxylic acid (100 mg, 0.523 mmol), thionyl chloride (0.85 mL, 11.7 mmol, 22 equiv.), tropine (81 
mg, 0.575 mmol, 1.1 equiv.) and n-butyllithium solution (1.1 equiv.). After two purifications by column 
chromatography (first: Alox neutral, CHCl3 / MeOH 995:5 to 99:1; second: silica gel, CH2Cl2/ MeOH 8:2 + 
0.5% aq NH3), 7-methoxy-tropisetron was obtained as a white solid (19 mg, 12% yield). 
1H NMR (DMSO-
d6) δ 1.73 (d, J=14.6, 2H, aliphatic-CH), 2.00 (br s, 4H, aliphatic-CH), 2.04 – 2.16 (m, 2H, aliphatic-CH), 
2.21 (s, 3H, N-Me), 3.09 (br s, 2H, aliphatic-CH), 3.94 (s, 3H, -OMe), 5.07 (t, J=5.1, 1H, -COO-CH-(CH2)2), 
6.78 (d, J=7.8, 1H, C(6)-H), 7.11 (t, J=7.9, 1H, C(5)-H), 7.62 (d, J=8.0, 1H, C(4)-H), 7.79 (d, J=3.0, 1H, C(2)-
H), 12.07 (s, 1H, NH). 1H NMR (CDCl3) δ 1.94 (d, J=14.9, 2H, aliphatic-CH), 2.03 – 2.21 (m, 4H, aliphatic-
CH), 2.26 – 2.42 (m, 2H, aliphatic-CH), 2.37 (s, 3H, N-Me), 3.24 (br s, 2H, aliphatic-CH), 3.96 (s, 3H, -
OMe), 5.27 (t, J=5.2, 1H, -COO-CH-(CH2)2), 6.71 (d, J=7.7, 1H, C(6)-H), 7.19 (t, J=8.0, 1H, C(5)-H), 7.78 – 
7.83 (m, 2H, C(2)-H and C(4)-H), 9.32 (s, 1H, NH). 13C NMR (CDCl3) δ 25.9, 36.5, 40.2, 55.5, 60.2, 66.5, 
103.1, 109.8, 113.9, 122.7, 126.9, 127.5, 130.2, 146.3, 164.6. HRMS (ESI+): exact mass calcd for 
C18H23N2O3 [M+H]
+ 315.1703, found 315.1704, Δ: 0.3 ppm. UHPLC (λ = 214 nm) tR = 2.27 min, 91% 
purity. 
N-8’-Benzyl-tropisetron ((1R,3r,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl 1H-indole-3-
carboxylate) was synthesized according to the general procedure, using 1H-indole-3-carboxylic acid (37 
mg, 0.23 mmol), thionyl chloride (0.3 mL, 4.14 mmol, 18 equiv.), endo-8-benzyl-8-
azabicyclo[3.2.1]octan-3-ol (50 mg, 0.23 mmol, 1 equiv.) and n-butyllithium solution (1.09 equiv.). After 
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purification by column chromatography (silica gel, CH2Cl2 / MeOH 95:5), N-8’-Benzyl-tropisetron was 
obtained as a white solid (18 mg, 22% yield). 1H NMR (DMSO-d6) δ 1.77 (d, J=15.0, 2H, aliphatic-CH), 
2.04 – 2.20 (m, 6H, aliphatic-CH), 3.14 (br s, 2H, aliphatic-CH), 3.55 (s, 2H, N-CH2-Ph), 5.16 (t, J=4.6, 1H, -
COO-CH-(CH2)2), 7.14 – 7.54 (m, 8H, Ar-H), 7.96 – 8.09 (m, 2H, Ar-H), 11.89 (s, 1H, NH). 
1H NMR (CDCl3) 
δ 1.86 (d, J=15.0, 2H, aliphatic-CH), 2.00 – 2.18 (m, 4H, aliphatic-CH), 2.30 (d, J=14.6, 2H, aliphatic-CH), 
3.23 (br s, 2H, aliphatic-CH), 3.59 (s, 2H, N-CH2-Ph), 5.25 (t, J=5.2, 1H, -COO-CH-(CH2)2), 7.13 – 7.31 (m, 
5H, Ar-H), 7.32 – 7.44 (m, 3H, Ar-H), 7.78 (d, J=2.9, 1H, C(2)-H), 8.10 – 8.22 (m, 1H, Ar-H), 8.93 (s, 1H, 
NH). 13C NMR (CDCl3) δ 26.2, 36.8, 56.6, 58.3, 67.1, 109.3, 111.8, 117.6, 121.4, 122.2, 123.4, 126.1, 
126.5, 128.6, 129.1, 130.9, 136.3, 164.5. HRMS (ESI+): exact mass calcd for C23H25N2O2 [M+H]
+ 
361.1911, found 361.1911, Δ: 0.0 ppm. UHPLC (λ = 214 nm) tR = 2.59 min, 99% purity. 
Site-directed mutagenesis: Mutagenesis was performed using the QuikChange method (Agilent 
Technologies Inc., California, USA. Cysteine residues were substituted for amino acids throughout each 
of the binding loops A - E (fig. 1). To facilitate comparisons with previous work, we have used the 
numbering of the equivalent residues in the mouse 5-HT3A subunit (Q6J1J7). 
Cell culture and transfection: Human embryonic kidney (HEK) 293 cells were grown on 90 mm 
round tissue culture plates as monolayers in DMEM / F12 (Gibco, Life Technologies, CA, USA) 
supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich) at 37°C in a moist atmosphere 
containing 5% CO2.   
Human 5-HT3A subunit cDNA (Accession: P46098, kindly provided by J. Peters, Dundee 
University, UK) was cloned into pcDNA3.1 for expression in HEK293 cells. The α7 nACh receptor was a 
chimaera of the chick α7 nACh extracellular domain fused to the 5-HT3 transmembrane / intracellular 
domains as described by Eiselé et al. (1993) and was similarly cloned into pcDNA3.1. Cells were 
transiently transfected with either of these cDNA constructs using polyethyleneimine (PEI: 25 kDa, 
linear, powder, Polysciences Inc., Eppelheim, Germany). 30 µl of PEI (1 mg ml−1), 5 μg cDNA and 1 ml 
DMEM were incubated for 10 min at room temperature, added drop wise to a 90mm plate of 70 - 80% 
conﬂuent HEK293 cells, and incubated for 2-3 days before use. 
Radioligand Binding: Transfected HEK 293 cells were scraped into 0.6 ml of ice-cold 10 mM 
HEPES buffer (pH 7.4) and frozen. After thawing, they were washed with HEPES buffer, homogenised by 
trituration through a 25 gauge (0.5 mm) needle, and 50 µg of cell suspension incubated in 0.5 ml HEPES 
buffer containing different concentrations of radioligand. Non-specific binding was determined using 
100 µM granisetron (with [3H]tropisetron), 100 µM tropisetron (with [3H]granisetron), or 30 µM - / -
nicotine (with [3H]epibatidine). Equilibrium reactions were incubated on ice for at least 1 h and 
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terminated by vacuum filtration onto Whatman GF/B filters wetted with 0.3 % polyethyleneimine, 
followed by two rapid washes with 2.5 ml ice cold buffer. Radioactivity was measured by scintillation in 
Ultima Gold XR (Perkin Elmer, Waltham, MA) using a Tri-Carb 2100TR (PerkinElmer) scintillation 
counter. Final counts were monitored to ensure that binding never exceeded 10% of the added 
concentrations of radioligands. For mutants that showed poor expression (D69C, H185C), Bmax values 
were compared using paired samples of wild type and mutant receptor prepared under identical 
conditions on the same day. 
Competition binding at α7 nACh receptors (10 point) was determined by incubating 
preparations of HEK 293 cells transfected with the α7 nACh receptor in 0.5 ml HEPES buffer containing 
7 nM [3H]epibatidine and differing concentrations of the competing ligands granisetron (maximal 
concentration used = 30 µM) or tropisetron (max = 300 µM). Non-specific binding was determined with 
30 µM - / -nicotine. Equilibrium reactions were incubated on ice for at least 1 h and bound radioligand 
measured using the same method as described above. 
Data Analysis: All data were analysed using GraphPad Prism v5. Individual saturation binding 
experiments were fitted to the equation below and the fitted values averaged to yield mean ± sem of n 
independent experiments: 
 
 
where Bmax is maximum binding at equilibrium, Kd is the equilibrium dissociation constant and [L] is the 
free concentration of radioligand. Affinities were compared using 1-way ANOVA and a Dunnett’s Post-
Test. 
 Detection: 48 hours post transfection, HEK293 cells were harvested in 10 ml phosphate 
buffered saline (137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 2 mM KH2PO4, pH 7.4), centrifuged 5 min 
at 220 g and the pellets stored at -80 °C. Total extracts were prepared by resuspension of 1 x 107 cells in 
1 ml lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 2 mM EDTA, 5 mM MnSO4, 4 x Halt Protease 
Inhibitor (Thermo Fisher Scientific), 0.2 mg ml-1 RNase A (Sigma-Aldrich), 500 U ml-1 Cyanase 
(RiboSolutions, TX, USA), 0.1 % Triton X-100) followed by 30 mins on ice. Extracts were supplemented 
with NuPage LDS buffer (Thermo Fischer Scientific) and heated at 70 oC for 10 min. 105 cell equivalents 
were loaded on a 4 - 12% Bis-Tris NuPage gel and blotted on nitrocellulose using the iBlot system 
(ThermoFisher Scientific). 5-HT3 receptors were detected with 1:250 mouse monoclonal antibody (sc-
390168; Santa Cruz Biotechnology, TX, USA) and 1:10000 goat anti-Mouse IRDye800CW (925-32210; LI-
COR Biosciences, NE, USA). CPSF-100 served as a loading control and was detected using 1:10000 rabbit 
polyclonal antibody (kindly provided by Georges Martin & Walter Keller, University of Basel) and 
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1:10000 goat anti-Rabbit IRDye680LT (925-68021, LI-COR Biosciences). Signals were improved using 
SuperSignal Western Blot Enhancer (Thermo Fischer Scientific) according to the manufacturer’s 
instructions. 
Modelling and Docking: Using ClustalW, the protein sequence of the human 5-HT3A subunit 
(accession: P46098) was aligned with the amino acid sequences extracted from ligand-bound AChBP 
crystal structures (pdbid; 2WNC, 2YME). Five pentameric homology models were generated using 
Modeller 9.13 with default parameters and the best model selected using Ramachandran plot analysis.  
The three-dimensional and protonated structure of tropisetron was constructed using Chem3D 
Pro v14.0 (CambridgeSoft, Cambridge, UK) and was based on the crystal structure of N1-methylated 
tropisetron extracted from the Cambridge Structural Database (CSD access code BEGLEG). The 
generated ligand was subsequently energy-minimised using the implemented MM2 force field.  
The binding site in the 5-HT3 receptor was defined as being within 10 Å of the centroid of the 
aromatic side-chain of W183, a residue that is centrally located in the binding site and known to be 
important for the binding of competitive ligands (Thompson et al., 2010). Potential ligand-receptor 
interactions were identified in each of the following four structures, A) a co-crystal structure of 
tropisetron and AChBP (2WNC), B) a co-crystal structure of granisetron and AChBP (2YME), C) 
tropisetron docked into a 5-HT3 receptor homology model based upon 2WNC, and D) tropisetron 
docked directly into 2YME. Tropisetron was docked using GOLD Suite v5.3 (The Cambridge 
Crystallographic Data Centre, Cambridge, UK) with the GoldScore function and default settings. During 
docking the carbonyl linker of tropisetron was defined as rigid as it is known that the planarity and 
rigidity of this bond is crucial for high-affinity binding (Hibert, 1994). For each of the two homology 
models, ten docking poses were generated. For 2WNC and 2YME the native poses were used. This 
analysis yielded 22 independent ligand poses. All residues within 5 Å of the ligand were identified in 
each of the ligand poses and these residues and their potential hydrogen bond interactions visualised 
using PyMol v1.3.  
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FIGURE LEGENDS 
 
Fig 1. Positions of the residues mutated in this study. (A) A cartoon showing the orthosteric binding site 
of the 5-HT3 receptor formed by binding loops A - F. The extracellular binding site is found at the 
interface of two adjacent subunits. For clarity only two subunits are shown. (B) An amino acid sequence 
alignment showing the positions of mutated residues (white text, black boxes). The six recognised 
binding loops are shown as grey lines. The proteins are sequences from human 5-HT3A (P46098), 
mouse 5-HT3A (Q6J1J7), chick α7 nACh (F1P4Y5) and sequences taken from the AChBP crystal 
structures 2YME, 2WNC and 3SQ6. c_α7nACh and h_5HT3 are the sequences of receptors used in the 
binding studies presented here. EMBOSS Needle shows that the sequence of 2WNC_AChBP has a closer 
identity and similarity to c_α7nACh (Id= 27.4 %; Sim = 41.8 %) than to h_5HT3 (Id= 19.4 %; Sim = 31.8 
%) (Rice et al., 2000). To facilitate comparisons with previous work, the numbering used throughout 
this manuscript refers to residues at equivalent positions of the mouse 5-HT3A subunit (Q6J1J7). 
 
Fig 2. Binding of tropisetron. Predicted binding clusters for tropisetron docked into (A) a homology 
model of the 5-HT3 receptor binding site based upon the template 2WNC (Model-1), and (B) the crystal 
structure 2YME (Model-2). (C) Co-crystal structures 2WNC and 2YME show AChBP bound with 
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tropisetron and granisetron respectively. In panels 2A & 2B all 10 predicted ligand poses are overlaid. 5-
HT3 receptor residues within 5 Å of tropisetron in each of these poses are shown in table 1.  
 
Fig 3. Binding site residues and the corresponding change in affinity when they are mutated. All 
positions in this figure are shown as cysteine and are colour coded according to the extent of the 
change in affinity this mutation caused. Residues that are thought to have a structural role have been 
omitted. The structure is Model-1, and more details of the effects of these cysteine substitutions can be 
found in tables 2 & 3.  
 
Fig 4. Expression of mutant 5-HT3 receptors. Three of the mutant receptors did not bind either 
[3H]tropisetron or [3H]granisetron (W90C, E129C, W183C). To confirm that this could be attributed to 
altered binding rather than changes in expression, these mutants were probed by Western blot using a 
5-HT3 receptor-specific antibody. Expression of the mutants and wild type receptors were comparable, 
and there was no detection in untransfected cells. In each lane 105 cell equivalents were loaded and an 
antibody against the cleavage and polyadenylation specificity factor (CPSF) included as an internal 
control. Note that whole-cell homogenates were used for both radioligand binding and Western blot to 
enable monitoring of the same populations of both intracellular and cell-surface receptors. 
 
Fig 5. The three docked-pose clusters predicted by docking tropisetron into a homology model of the 5-
HT3 receptor that was based on the template 2WNC (Model-1). Representative orientations of 
tropisetron are shown for each of the clusters A, B and C (for an overlay of all docked poses see fig 2A). 
In panel 5D, tropisetron (Cluster-A, pink), and granisetron (2YME, green) are overlaid. The residues 
shown are those that abolished binding in fig 3 (Cluster-A, red; 2YME, cyan). Other residues are omitted 
for clarity. For a full list of the identified residues in Cluster-A and 2YME see table 1. The docked-pose 
predicted in Cluster-A is the most consistent with the binding results presented here.  
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Table 1. Residues predicted to be within 5Å of tropisetron or granisetron in the 5-HT3A receptor binding site. 
 Principal Face 
 Complementary Face 
Protein* Loop A Loop B Loop C    Loop D  Loop E 
Model-1 
Tropisetron 
L
1
2
6
 
I
1
2
7
 
N
1
2
8
 
E
1
2
9
 
T
1
7
9
 
F
1
8
0
 
T
1
8
1
 
S
1
8
2
 
W
1
8
3
 
L
1
8
4
 
H
1
8
5
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2
2
8
 
E
2
2
9
 
S
2
3
0
 
S
2
3
1
 
N
2
3
2
 
Y
2
3
4
 
A
2
3
5
 
E
2
3
6
 
 
 D
6
9
 
I
7
1
 
W
9
0
 
R
9
2
 
K
1
1
2
 
Y
1
4
1
 
V
1
4
2
 
Y
1
4
3
 
V
1
5
0
 
Q
1
5
1
 
N
1
5
2
 
Y
1
5
3
 
K
1
5
4
 
P
1
5
5
 
1   *  * * * * * *  *  *  * * * *    *     *  * * *   
2 *  *  *  * * * * * *  *  * * * *    *   * * *  * * *   
3 * * *  * * * * * *  * * *  * * * *    * *      *  *   
4   * * * * * * * *  *  *  * * * *    *     *  *  *   
5 * * *  * * * * * *  * * *  * * * *    * *      *  *   
6   *         * * * * * *      *  *   *  *  *  * 
7   *  * * * * * * * * * *   * * *  * * * *     * *  *   
8   *  *  * * * * * * * *   * * *  * * * *        *   
9 *  *  * * * * * * * *  *  * * * *    *   * * *  *  *   
10 * * *  * * * * * *  * * *  * * * *    * *      *  *   
Model-2 
Tropisetron 
T
 
 
Y
 
    
S
 
W
 
V
 
 
Y
 
S
 
C
 
C
 
P
 
Y
 
   
T
 
 
W
 
R
 
     
M
 
 
I
 
P
 
 
1   *     * * *  *  * * * *      * *      *  *   
2   *     * * *  *  * * * *      * *      *  *   
3   *     * * *  *  * * * *      * *      *  *   
4   *     * * *  *  * * * *      * *      *  *   
5   *     * * *  *  * * * *      * *      *  *   
6   *     * * *  *  * *  *      * *      *  *   
7   *     * * *  *  * *  *    *  * *      *  *   
8   *     * * *  *  * *  *    *  * *      *  *   
9   *     * * *  *  * * * *      * *      *  *   
10 *  *     * * *  * * * *  *      * *      *  * *  
2WNC 
Tropisetron 
  
Y
 
    
S
 
W
 
  
Y
 
 
C
 
C
 
 
Y
 
    
T
 
Y
 
Q
 
     
M
 
 
I
 
  
   *     * *   *  * *  *     * * *      *  *   
2YME 
Granisetron 
  
Y
 
     
W
 
     
C
 
 
Y
 
    
T
 
Y
 
Q
 
     
M
 
 
I
 
  
   *      *      *  *     * * *      *  *   
 
* Model-1 = tropisetron docked into a 5-HT3 receptor homology model that was based on the the template 2WNC (docked poses 1, 2, 4, 6 
& 9 = Cluster-A; 3, 5 & 10 = Cluster-B; 7 & 8 = Cluster-C; see fig 5). Model-2 = tropisetron docked directly into the granisetron-bound AChBP 
structure 2YME. 2WNC & 2YME are residues identified directly from the co-crystal structures of AChBP bound with the ligand shown. 
Aligning residues shown in this table can also be found in fig 1. Equivalent residues from Model-2, 2WNC and 2YME are shown, but the 
their numbers are removed for clarity. To facilitate comparisonswith previosu studies, the numbering of the residues are based on the 
equivalent positions in the mouse 5-HT3A subunit (Q6J1J7). Grey shading indicates that the residue has been identified as being within 5Å 
in the docked-pose listed on the left. Images of the ligand orientations can be found in figs 2 & 5. 
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Table 2. Saturation binding of [3H]tropisetron at 5-HT3A receptor cysteine mutants. 
Loop Mutant 
pKd 
(± SEM) 
n 
Kd 
(nM) 
Log Difference ± SED 
            
 
Wild type 9.15 ± 0.06 8 0.72  
 D69C NB* 5 -  
 I71C 8.87 ± 0.08 8 1.36  
 W90C NB* 8 -  
 R92C 8.74 ± 0.04* 7 1.82  
 L126C 8.75 ± 0.10* 6 1.79  
 N128C 8.14 ± 0.04* 6 7.28  
 E129C NB* 9 -  
 Y143C NB* 7 -  
 Q151C 8.95 ± 0.04 8 1.11  
 Y153C 8.70 ± 0.07* 7 1.99  
 P155C 8.44 ± 0.16* 5 3.60  
 T179C 8.86 ± 0.08 5 1.38  
 T181C 8.23 ± 0.09* 7 5.85  
 W183C NB* 7 -  
 L184C 8.85 ± 0.11 7 1.41  
 H185C NB* 7 -  
 M228C 8.69 ± 0.07* 5 2.04  
 E229C 8.35 ± 0.11* 6 4.51  
 S230C 9.43 ± 0.03 5 0.37  
 S231C 8.92 ± 0.16 6 1.20  
 N232C 9.02 ± 0.11 5 0.96  
 Y234C NB* 5 -  
 E236C 8.30 ± 0.08* 6 5.03  
 * = significantly different (1-way ANOVA and a Dunnett’s Post-Test) to wild type receptors. SED = 
standard error of the difference. 
D 
A 
E 
B 
C 
 1 -1 0 
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Table 3. Saturation binding of [3H]granisetron at 5-HT3A receptor cysteine mutants.  
Loop Mutant 
pKd 
(± SEM) 
n 
Kd 
(nM) 
Log Difference ± SED 
            
 
Wild type 9.33 ± 0.11 6 0.46  
 D69C 9.51 ± 0.07 5 0.31  
 I71C 8.81 ± 0.17* 4 1.57  
 W90C NB* 5 -  
 R92C NB* 8 -  
 L126C 9.22 ± 0.18 4 0.60  
 N128C 9.53 ± 0.10 5 0.29  
 E129C NB* 4 -  
 Y143C 9.42 ± 0.15 5 0.38  
 Q151C 9.32 ± 0.08 4 0.48  
 Y153C 8.84 ± 0.02* 6 1.43  
 P155C 9.29 ±0.02 3 0.51  
 T179C 8.92 ±.10* 4 1.21  
 T181C NB* 5 -  
 W183C NB* 8 -  
 L184C 9.55 ± 0.03 3 0.28  
 H185C 9.43 ± 0.09 3 0.37  
 M228C 9.34 ± 0.05 3 0.46  
 E229C 9.31 ± 0.04 3 0.49  
 S230C 9.84 ± 0.08* 3 0.15  
 S231C 9.63 ± 0.13 6 0.24  
 N232C 9.53 ± 0.09 4 0.30  
 Y234C 8.26 ± 0.15* 4 5.51  
 E236C 9.09 ± 0.09 3 0.82  
 * = significantly different (1-way ANOVA and a Dunnett’s Post-Test) to wild type receptors. SED = 
standard error of the difference. 
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Table 4. Affinities determined from binding tropisetron, granisetron and their analogues. 
Compound R R’ 
pKi  
Mean ± SEM 
Ki (nM) n 
Fold 
change 
Tropisetron Derivatives 
Parent Scaffold H CH3 9.15 ± 0.06 0.72 8 - 
1 5-OMe CH3 7.02 ± 0.03 95.5 4 133 
2 6-OMe CH3 6.74 ± 0.04 182 4 253 
3 7-OMe CH3 7.52 ± 0.12 30.2 4 42 
4 H Bn 5.84 ± 0.20 1445 6 2007 
Granisetron Derivatives 
Parent Scaffold H CH3 9.33 ± 0.11 0.47 6 - 
5 5-OMe CH3 5.27 ± 0.02 5370 4 >10000 
6 6-OMe CH3 6.35 ± 0.18 447 5 951 
7 7-OMe CH3 6.92 ± 0.24 120 7 255 
8 H Bn 6.72 ± 0.24 190 6 404 
* The structures below show tropisetron and granisetron with example saturations binding curves. 
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Fig 1 
A 
 
B 
 
           
h_5HT3A           RKPTTVSIDVIVYAILNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSI 
m_5HT3A           RKPTTVSIDVIMYAILNVDEKNQVLTTYIWYRQYWTDEFLQWTPEDFDNVTKLSIPTDSI 
c_α7nACh          SQPLTVYFTLSLMQIMDVDEKNQVLTTNIWLQMYWTDHYLQWNVSEYPGVKNVRFPDGLI 
2WNC_AChBP        --PLTVTLGFTLQDIVKADSSTNEVDLVYYEQQRWKLNSLMWDPNEYGNITDFRTSAADI 
2YME_5HTBP        --PLTVTLGFTLQDIVKVDSSTNEVDLVYWERQRWKLNSLMWDPNEYGNITDFRTSAADI 
3SQ6_α7nAChBP     R-PVTVYFSLSLLQIMDVDEKNQVVDVVFWLQMSWTDHYLQWNVSEYPGVKQVSVPISSL 
  61        120 
 
 
 
h_5HT3A           WVPDILINEFVDVGKSPNIPY-VYIRHQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLT  
m_5HT3A           WVPDILINEFVDVGKSPNIPY-VYVHHRGEVQNYKPLQLVTACSLDIYNFPFDVQNCSLT 
c_α7nACh          WKPDILLYNSADERFDATFHTNVLVNSSGHCQYLPPGIFKSSCYIDVRWFPFDVQKCNLK 
2WNC_AChBP        WTPDITAYSSTRP-VQVLSPQIAVVTHDGSVMFIPAQRLSFMCDPTGVDSEEGAT-CAVK 
2YME_5HTBP        WTPDITAYSSTRP-VQVLSPQIAVVTHDGSVMFIPAQRLSFMCDPTGVDSEEGVT-CAVK 
3SQ6_α7nAChBP     WVPDLAAYNAISK-PEVLTPQLALVNSSGHVQYLPSIRQRFSCDVSGVDTESGAT-CKLK 
         121        179 
 
 
 
h_5HT3A   FTSWLHTIQDINITLWRLPEKVKSDRSVFMNQGEWELLGVLP--YFREFSMESSNYYAEM 
m_5-HT3A          FTSWLHTIQDINITLWRSPEEVRSDKSIFINQGEWELLEVFP--QFKEFSIDISNSYAEM 
c_α7nACh          FGSWTYGGWSLDLQMQEADISG------YISNGEWDLVGIPGKRTESFYECCKEP-YPDI 
2WNC_AChBP        FGSWVYSGFEIDLKTDTDQVDLSS----YYASSKYEILSATQTRQVQHYSCCPEP-YIDV 
2YME_5HTBP        FGSWVYSGFEIDLKTDTDQVDLSS----YYASSKYEILSATQTRQVQHYSCCPEP-YIDV 
3SQ6_α7nAChBP     FGSWTHHSRELDLQMQEADISG------YIPYSRFELVGVTQKRSERFYECCKEP-YPDV 
         180                                                           234 
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Fig 5  
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• The drugs granisetron and tropisetron are structurally similar 
• Crystals of them bound to AChBP suggest they have similar binding orientations   
• At 5-HT3R, the effects of mutagenesis indicate that their orientations differ 
• SAR on both of these drugs also supports different orientations 
 
